Bupropion HCL ER

Solicitation SPE2D2-21-R-0105 is a lowest price technically acceptable (LPTA) acquisition for pharmaceutical products, seeking one award. Offerors must submit two volumes electronically via DIBBS: Volume 1 (non-price proposal) includes technical requirements (Tabs A-F, including country of origin certifications, subcontracting plans, and past performance documentation demonstrating compliance with FDA regulations), and Volume 2 (price proposal) details pricing for six line items (CLINs 0001-0006) with telephonic/email negotiations possible to determine the lowest evaluated unit price per bottle. Critical requirements include a Letter of Commitment/Certification, demonstration of FDA compliance (including disclosure of any violations or failed inspections within three years prior to solicitation issuance), and adherence to the Veterans’ Health Care Act of 1992 Federal Ceiling Price (FCP) policy. The offer must include a unique entity identifier and comply with various representations and certifications, including those related to restricted business operations in Sudan, contracting with inverted domestic corporations, and transactions with Iran. Offers must be submitted in US Dollars and include a unique eleven-digit National Drug Code (NDC) for each product. The government will evaluate offers by adding the total price for all options to the total price for the basic requirement. The contract will be awarded to the responsible offeror with the lowest evaluated aggregate price and a technically acceptable proposal.

Notice ID

d2713ea231544d89b653a39e3fbe278e

Solicitation Number

SPE2D2-21-R-0105

NAICS Code

325412

Classification Code

6505